福安药业9月9日获融资买入1232.04万元，融资余额4.52亿元

Core Insights - Fu'an Pharmaceutical experienced a stock decline of 1.30% on September 9, with a trading volume of 71.88 million yuan [1] - The company reported a financing buy-in of 12.32 million yuan and a net financing buy of 507,300 yuan on the same day [1] - As of September 9, the total financing and securities lending balance for Fu'an Pharmaceutical was 452 million yuan, representing 8.37% of its market capitalization [1] Financing Summary - On September 9, Fu'an Pharmaceutical had a financing buy-in of 12.32 million yuan, with a current financing balance of 452 million yuan, which is above the 90th percentile of the past year [1] - The securities lending data showed no shares were repaid or sold on September 9, with a remaining securities lending balance of 1,362 yuan, indicating a high level compared to the past year [1] Company Overview - Fu'an Pharmaceutical, established on February 25, 2004, and listed on March 22, 2011, is based in Chongqing and primarily engages in the research, production, and sales of antibiotic raw materials and formulations [1] - The company's revenue composition includes 56.60% from formulations, 39.44% from raw materials and intermediates, 3.55% from other sources, and 0.41% from drug distribution and others [1] Shareholder and Financial Performance - As of August 29, Fu'an Pharmaceutical had 40,900 shareholders, an increase of 1.67%, with an average of 23,695 circulating shares per person, a decrease of 1.64% [2] - For the first half of 2025, the company reported a revenue of 921 million yuan, a year-on-year decrease of 35.76%, and a net profit attributable to shareholders of 113 million yuan, down 47.74% year-on-year [2] - Since its A-share listing, Fu'an Pharmaceutical has distributed a total of 666 million yuan in dividends, with 178 million yuan distributed over the past three years [2] - As of June 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 5.45 million shares, a decrease of 5.04 million shares from the previous period [2]